Intellectual Disability
|
group |
Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Mental Disorders; Behavior and Behavior Mechanisms
|
Mental or Behavioral Dysfunction
|
2165
|
159
|
0.100 |
None |
|
0 |
|
|
|
Aphasia
|
disease |
Pathological Conditions, Signs and Symptoms; Nervous System Diseases
|
Mental or Behavioral Dysfunction
|
86
|
3
|
0.100 |
None |
|
0 |
|
|
|
Abnormality of vision
|
disease |
|
Finding
|
127
|
8
|
0.100 |
None |
|
0 |
|
|
|
Alzheimer Disease, Late Onset
|
disease |
Nervous System Diseases; Mental Disorders
|
Mental or Behavioral Dysfunction
|
385
|
243
|
0.400 |
None |
0.917 |
24 |
3
|
2007 |
2018 |
Low density lipoprotein cholesterol measurement
|
phenotype |
|
Laboratory Procedure
|
483
|
1142
|
0.100 |
None |
1.000 |
11 |
6
|
2008 |
2019 |
Serum LDL cholesterol measurement
|
phenotype |
|
Laboratory Procedure
|
269
|
555
|
0.100 |
None |
1.000 |
7 |
4
|
2008 |
2013 |
C-reactive protein measurement
|
phenotype |
|
Laboratory Procedure
|
135
|
624
|
0.100 |
None |
1.000 |
6 |
5
|
2008 |
2019 |
Alzheimer's Disease
|
disease |
Nervous System Diseases; Mental Disorders
|
Disease or Syndrome
|
3397
|
1843
|
0.500 |
None |
0.978 |
92 |
29
|
2009 |
2020 |
Serum total cholesterol measurement
|
phenotype |
|
Laboratory Procedure
|
486
|
1243
|
0.100 |
None |
1.000 |
6 |
6
|
2009 |
2019 |
High density lipoprotein measurement
|
phenotype |
|
Laboratory Procedure
|
545
|
1440
|
0.100 |
None |
1.000 |
5 |
5
|
2009 |
2019 |
Serum HDL cholesterol measurement
|
phenotype |
|
Laboratory Procedure
|
283
|
679
|
0.100 |
None |
1.000 |
3 |
2
|
2009 |
2013 |
Autoantibody measurement
|
phenotype |
|
Laboratory Procedure
|
27
|
52
|
0.100 |
None |
1.000 |
1 |
3
|
2009 |
2009 |
Carotid Artery Diseases
|
group |
Nervous System Diseases; Cardiovascular Diseases
|
Disease or Syndrome
|
69
|
6
|
0.010 |
None |
1.000 |
1 |
1
|
2009 |
2009 |
Mild cognitive disorder
|
disease |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
430
|
96
|
0.050 |
None |
0.800 |
5 |
5
|
2011 |
2018 |
Cognitive changes
|
phenotype |
Pathological Conditions, Signs and Symptoms; Nervous System Diseases
|
Mental or Behavioral Dysfunction
|
50
|
15
|
0.020 |
None |
0.500 |
2 |
|
2011 |
2019 |
Longevity
|
phenotype |
|
Temporal Concept
|
48
|
74
|
0.100 |
None |
1.000 |
2 |
1
|
2011 |
2012 |
Huntington Disease
|
disease |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases; Mental Disorders
|
Disease or Syndrome
|
978
|
115
|
0.020 |
None |
1.000 |
2 |
|
2011 |
2017 |
Coronary heart disease
|
disease |
Cardiovascular Diseases
|
Disease or Syndrome
|
1576
|
1178
|
0.100 |
None |
1.000 |
2 |
2
|
2011 |
2011 |
Charcot-Marie-Tooth disease, Type 2A
|
disease |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases
|
Disease or Syndrome
|
7
|
3
|
0.010 |
None |
1.000 |
1 |
|
2011 |
2011 |
Psychotic Disorders
|
group |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
560
|
179
|
0.310 |
None |
< 0.001 |
1 |
|
2011 |
2011 |
Optic Atrophy 1
|
disease |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Eye Diseases; Nervous System Diseases
|
Disease or Syndrome
|
117
|
45
|
0.010 |
None |
1.000 |
1 |
|
2011 |
2011 |
B-Cell Lymphomas
|
group |
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases
|
Neoplastic Process
|
1408
|
42
|
0.010 |
None |
1.000 |
1 |
|
2011 |
2011 |
Nonorganic psychosis
|
disease |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
376
|
98
|
0.310 |
None |
< 0.001 |
1 |
|
2011 |
2011 |
Pseudocholinesterase Measurement
|
phenotype |
|
Laboratory Procedure
|
39
|
568
|
0.100 |
None |
1.000 |
1 |
1
|
2011 |
2011 |
Triglycerides measurement
|
phenotype |
|
Laboratory Procedure
|
563
|
1418
|
0.100 |
None |
1.000 |
5 |
5
|
2012 |
2019 |